This can be explained by the notion that both RAS inhibition and PP2A reactivation inhibit phosphorylation of sites that are constitutively phosphorylated in cancer cells, and based on the recent model that most of the cellular phosphosites are exclusively dominated by either phosphatase activation or inhibition (Kauko et al, 2020). This evidence concerns the gene PTPA and cancer.